WHO ICTRP trial
Study of the usefulness of neoadjuvant chemo-hormone therapy for high-risk…
JPRN-UMIN000030346 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000030346 |
|---|---|
| Public title | Study of the usefulness of neoadjuvant chemo-hormone therapy for high-risk prostate cancer |
| Scientific title | Study of the usefulness of neoadjuvant chemo-hormone therapy for high-risk prostate cancer - Neoadjuvant chemo-hormone therapy for high-risk prostate cancer |
| Primary sponsor | Fujita Health University Hospital |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Prostate cancer |
| Interventions | Degaarelix and estramustine would be preoperatively administared for 3 months. |
| Registration date | Nov 12, 2017 |
| Target size | 10 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: